Emil D. Kakkis, President & CEO at Ultragenyx Pharmaceutical Inc. (RARE), sold 54,404 shares at $22.80 ($1.2M) on 2026-03-02, disclosed to the SEC on 2026-03-03.
Seasonal sale ($1.2M) by President & CEO — this insider has traded RARE in March in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| Filing → |
| RARE | SELL | 2024-12-11 | $414K | — | Filing → |
| RARE | SELL | 2024-09-05 | $1.1M | — | Filing → |
| RARE | SELL | 2024-08-07 | $1.0M | — | Filing → |